The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients

Tyrosine-kinase inhibitors (TKIs) have revolutionized cancer therapy in recent years. Although more targeted than conventional chemotherapy, TKIs exhibit substantial cardiotoxicity, often manifesting as hypertension or heart failure. Here, we assessed myocyte intrinsic cardiotoxic effects of the TKI...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Christopher, Wallner, Markus, Kolesnik, Ewald, Herbst, Viktoria, Mächler, Heinrich, Pichler, Martin, von Lewinski, Dirk, Sedej, Simon, Rainer, Peter P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871797/
https://www.ncbi.nlm.nih.gov/pubmed/29593308
http://dx.doi.org/10.1038/s41598-018-23630-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871797/
https://www.ncbi.nlm.nih.gov/pubmed/29593308
http://dx.doi.org/10.1038/s41598-018-23630-w

Ejemplares similares